skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Galeterone (Code C84866)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Galeterone

Definition: An orally bioavailable small-molecule androgen receptor modulator and CYP17 lyase inhibitor with potential antiandrogen activity. Galeterone exhibits three distinct mechanisms of action: 1) as an androgen receptor antagonist, 2) as a CYP17 lyase inhibitor and 3) by decreasing overall androgen receptor levels in prostate cancer tumors, all of which may result in a decrease in androgen-dependent growth signaling. Localized to the endoplasmic reticulum (ER), the cytochrome P450 enzyme CYP17 (P450C17 or CYP17A1) exhibits both 17alpha-hydroxylase and 17,20-lyase activities, and plays a key role in the steroidogenic pathway that produces progestins, mineralocorticoids, glucocorticoids, androgens, and estrogens.

Display Name: Galeterone

Label: Galeterone

NCI Thesaurus Code: C84866 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2830126  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Androsta-5,16-dien-3-ol, 17-(1h-benzimidazol-1-yl)-, (3beta)-
Specific Androgen Receptor Modulator/CYP17 Lyase Inhibitor TOK-001

External Source Codes: 
CAS Registry Number 851983-85-2 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 653977
PDQ Open Trial Search ID 653977 (check for NCI PDQ open clinical trial info)
UMLS CUI C2830126

Other Properties:
     Name Value (qualifiers indented underneath)
Chemical_Formula C26H32N2O
code C84866
Contributing_Source CTRP
Contributing_Source FDA
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom